Characterization of host immunity to cytomegalovirus pp150 (UL32)

被引:23
作者
La Rosa, C [1 ]
Wang, ZD [1 ]
Lacey, SF [1 ]
Markel, SF [1 ]
Sharma, MC [1 ]
Martinez, J [1 ]
Lalimarmo, MM [1 ]
Diamond, DJ [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Lab Vaccine Res, Duarte, CA 91010 USA
关键词
CMV; pp150; epitope mapping; recombinant MVA;
D O I
10.1016/j.humimm.2004.10.008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The basic phosphoprotein 150 (pp150), the product of UL32 (unique long domain 32) gene of human cytomegalovirus (CMV), is an abundant component of the viral tegument and a target of human leukocyte antigen (HLA)-restricted cytotoxic T cells (CTLs) after infection. Identification of minimal cytotoxic epitopes (MCEs) from this CMV protein is of importance for peptide-based vaccines and immunotherapeutic approaches. Several pp150-specific CTL clones were derived from peripheral blood mononuclear cells of healthy CMV-positive donors with autologous fibroblasts infected either with CMV AD169 or with a recombinant vaccinia virus expressing full-length pp150 protein. HLA A*0301- and HLA A*6801-restricted CD8(+) pp150 T-cell clones derived from different donors were found to efficiently kill autologous CMV-infected fibroblasts. Fine mapping of each MCE first used a T-cell epitope prediction algorithm. Overlapping peptides within the recognized regions were screened. The analysis identified pp150(792-802) and pp150(945-955) as MCEs for the HLA A*6801 and the HLA A*0301 pp150 clones, respectively. In vitro stimulation by recombinant modified vaccinia Ankara virus expressing full-length pp150 elicited high frequencies of CMV-CTL and interferon gamma production specific for the MCE identified in all subjects. The consistent presence of pp150 T cells in CMV-exposed individuals Supports a role for this antigen in shaping the antiviral CTL response and indicates that pp150 could be a pivotal constituent of prophylactic and therapeutic CMV vaccines. (C) American Society for Histocompatibility and Immunogenetics, 2005. Published by Elsevier Inc.
引用
收藏
页码:116 / 126
页数:11
相关论文
共 64 条
[1]   Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus [J].
Akiyama, Y ;
Maruyama, K ;
Mochizuki, T ;
Sasaki, K ;
Takaue, Y ;
Yamaguchi, K .
IMMUNOLOGY LETTERS, 2002, 83 (01) :21-30
[2]  
[Anonymous], 2000, The HLA Facts Book
[3]   Cytomegalovirus basic phosphoprotein (pUL32) binds to capsids in vitro through its amino one-third [J].
Baxter, MK ;
Gibson, W .
JOURNAL OF VIROLOGY, 2001, 75 (15) :6865-6873
[4]   Isolation and expansion of human cytomegalovirus-specific cytotoxic T lymphocytes using interferon-γ secretion assay [J].
Bissinger, AL ;
Rauser, G ;
Hebart, H ;
Frank, F ;
Jahn, G ;
Einsele, H .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (10) :1178-1184
[5]  
Bowen EF, 1996, AIDS, V10, P1515, DOI 10.1097/00002030-199611000-00009
[6]   Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model [J].
Carroll, MW ;
Overwijk, WW ;
Chamberlain, RS ;
Rosenberg, SA ;
Moss, B ;
Restifo, NP .
VACCINE, 1997, 15 (04) :387-394
[7]   THE BINDING-AFFINITY AND DISSOCIATION RATES OF PEPTIDES FOR CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES [J].
CERUNDOLO, V ;
ELLIOTT, T ;
ELVIN, J ;
BASTIN, J ;
RAMMENSEE, HG ;
TOWNSEND, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (09) :2069-2075
[8]  
CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125
[9]   A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays [J].
Currier, JR ;
Kuta, EG ;
Turk, E ;
Earhart, LB ;
Loomis-Price, L ;
Janetzki, S ;
Ferrari, G ;
Birx, DL ;
Cox, JH .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 260 (1-2) :157-172
[10]   A COMPUTER-PROGRAM FOR PREDICTING POSSIBLE CYTOTOXIC T-LYMPHOCYTE EPITOPES BASED ON HLA CLASS-I PEPTIDE-BINDING MOTIFS [J].
DAMARO, J ;
HOUBIERS, JGA ;
DRIJFHOUT, JW ;
BRANDT, RMP ;
SCHIPPER, R ;
BAVINCK, JNB ;
MELIEF, CJM ;
KAST, WM .
HUMAN IMMUNOLOGY, 1995, 43 (01) :13-18